Acurx Pharmaceuticals Advances Ibezapolstat Trials with Recurrent CDI Focus

Event summary

  • Acurx raised $1.5M in Q4 2025 via equity line, ending 2025 with $7.6M cash.
  • Launched Phase 3-ready ibezapolstat trial for recurrent CDI (rCDI) in March 2026.
  • USPTO granted patent for Pol IIIC inhibitors extending to December 2039.
  • Phase 2 ibezapolstat results showed 96% clinical cure rate in 26 CDI patients.
  • FDA may reduce Phase 3 trial requirement from two to one for CDI approval.

The big picture

Acurx's focus on recurrent CDI with ibezapolstat positions it to address a critical unmet need in antibiotic-resistant infections. The potential FDA pathway reduction to a single Phase 3 trial could significantly streamline approval processes for novel antibiotics. With $7.6M in cash and strategic patents secured, the company is poised to advance its pipeline, though financing will remain a key factor in execution.

What we're watching

Regulatory Flexibility
Whether FDA's potential one-trial Phase 3 requirement will accelerate ibezapolstat's approval timeline.
Clinical Success
How the open-label rCDI trial results will inform the planned Phase 3 registration trial.
Funding Requirements
The pace at which Acurx can secure additional financing to support international Phase 3 trials.